Leung K Y, Ling Matina, Tang G W K
The University of Hong Kong, Queen Mary Hospital, Department of O and G, Hong Kong, Hong Kong.
Maturitas. 2005 Nov-Dec;52(3-4):277-85. doi: 10.1016/j.maturitas.2005.04.008. Epub 2005 Jun 9.
To determine the impact of Women Health Initiative (WHI) trial on the use of hormone replacement therapy (HRT) in the Hong Kong public health sector.
The central prescription database of the Hospital Authority was used to describe the half-yearly trend in the use of HRT between July 2000 and December 2003. The data of hysterectomy was retrieved from another clinical database.
Before the publication of the WHI trial in July 2002, conjugated equine estrogens (CEE) and its related products dominated HRT prescribing. Relative to the first half of 2002, there was an immediate and substantial decline by 43.5% in the prescriptions of combined CEE/progestogen products and a modest decline by 22.4% in the prescriptions of CEE-alone therapy in the second half of 2002. In the first half of 2003, a decline in the prescriptions of all HRT preparations except raloxifene was observed. However, in the second half of 2003, there were no more declines in overall HRT users. Relative to the first half of 2002, the decline in the overall HRT users in the first half of 2003 was more than 46% in women aged 50-69. The decline was greater in women with a history of hysterectomy (60.3%) than women without (38.6%), but was similar between gynaecology specialty (41.7%) and non-gynaecology specialty (43.9%).
Similar to the U.S., an immediate and substantial decline in the use of CEE and its related products was observed in Hong Kong after the publication of the WHI trial.
确定妇女健康倡议（WHI）试验对香港公共卫生部门激素替代疗法（HRT）使用情况的影响。
利用医院管理局的中央处方数据库描述2000年7月至2003年12月期间HRT使用的半年趋势。子宫切除术的数据从另一个临床数据库中获取。
在2002年7月WHI试验公布之前，结合马雌激素（CEE）及其相关产品在HRT处方中占主导地位。与2002年上半年相比，2002年下半年CEE/孕激素联合产品的处方量立即大幅下降了43.5%，单纯CEE疗法的处方量适度下降了22.4%。在2003年上半年，除雷洛昔芬外的所有HRT制剂的处方量均出现下降。然而，在2003年下半年，HRT总体使用者数量没有进一步下降。与2002年上半年相比，2003年上半年50 - 69岁女性中HRT总体使用者数量下降超过46%。有子宫切除术史的女性（60.3%）的下降幅度大于无子宫切除术史的女性（38.6%），但妇科专科（41.7%）和非妇科专科（43.9%）之间的下降幅度相似。
与美国类似，在WHI试验公布后，香港CEE及其相关产品的使用量立即大幅下降。
